This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Xolair
  • /
  • Evaluate the Effect of Omalizumab on Markers of As...
Clinical trial

Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

Read time: 1 mins
Last updated:1st Mar 2009

This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood Institute (NHBLI) Guidelines


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
Enrollment: 271
Study Start Date: March 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Omalizumab
- Placebo Comparator: Placebo

Category Value
Study start date 2009-03-01

View full details